Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
- Array Technologies holds investor showcase on balance-of-system strategy
- LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
